Navigation Links
Jazz Pharmaceuticals Announces Stockholder Vote in Favor of Transaction With Azur Pharma Limted
Date:12/12/2011

rated company, we look forward to building on our diverse portfolio of commercial products, strong balance sheet and efficient corporate structure for continued growth into the future."

About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet needs in neurology and psychiatry. For further information, see http://www.jazzpharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the business combination transaction between Jazz Pharmaceuticals and Azur Pharma and the timing and benefits thereof, the combined company's future financial results and growth potential and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Jazz Pharmaceuticals' ability to complete the transaction on the proposed terms and schedule; risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of th
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... N.C., Jan. 19, 2011 As Pisgah Laboratories, Inc. ... it will soon begin scale-up of its patent-pending form ... of hydrocodone which imparts abuse deterrent properties to a ... clinical trials in their FDA / DEA registered facility. ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... medical disposables and non-woven fabric made from 100% natural ... will participate in Arab Health 2011, to be held ... Exhibition Centre in Dubai, UAE. During ...
Cached Medicine Technology:Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 2Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 3Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 2Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 3
(Date:7/11/2014)... H.E.A.R Me Out Listens to Needs of ... to provide comprehensive information and services available to Colorado’s ... Coloradoans with hearing loss, this organization is the first ... the local and state resources that aims to give ... H.E.A.R. Me Out and its website was founded by ...
(Date:7/11/2014)... Having experienced mental illness from the perspectives ... hospital staff, Roger Grainger gives readers an intimate look at ... book, “You Never Get Out.” , According to the Mental ... will experience some kind of mental health problem in the ... take a look at the way mental illness is addressed ...
(Date:7/11/2014)... of personalized medicine may be just around the corner, ... Min Yu and scientists at Massachusetts General Hospital and ... in Science , Yu and her colleagues report ... blood streams of six patients. Some of these deadly ... to and establish secondary tumors in vital organs such ...
(Date:7/11/2014)... July 11, 2014 Cancer researchers in ... a significant impact on how patients respond to treatment ... mesothelioma. Surviving Mesothelioma has the full story. Click ... Researchers at the University of Ljubljana and the Ljubljana ... for different types of polymorphisms. They found that ...
(Date:7/11/2014)... Re-tearing a repaired knee Anterior Cruciate Ligament (ACL) ... presented today at the American Orthopaedic Society for Sports ... and patient education regarding modifiable risk factors may minimize ... “Our research suggests that a few risk factors such ... may point to the possibility of re-injury,” said lead ...
Breaking Medicine News(10 mins):Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Study May Identify Risk Factors for ACL Re-injury 2
... general practitioners , who were free of dementia ... years and 3 years later by means of ... alcohol consumption and DSM-IV dementia diagnoses. Associations between ... alcohol (wine, beer, mixed alcohol beverages) and incident ...
... 7, 2011 Elsevier, the leading global publisher ... announced today it has begun offering Arabic bilingual editions ... the Middle East. The first order was recently received ... one of Elsevier,s many meant to help improve the ...
... , The U.S. spends around 2 billion dollars a ... large portion of this used for groundwater monitoring. Yet ... University,s Biodesign Institute, the information gathered is often of ... grant from the U.S. Department of Defense, Halden, assistant ...
... The 2011 Sleep in America poll released today by the National ... hour before bed. It also finds that a significant number of ... searching for ways to cope. , Many Americans report dissatisfaction ... 43% of Americans between the ages of 13 and 64 say ...
... heart disease, involving scientists from the University of ... of heart attacks. Professor Nilesh Samani, British ... Leicester, based at Glenfield Hospital, who co-led the international ... genes identified were not previously known to be involved ...
... Creating a healthy eating action plan and visualizing yourself carrying ... suggest. "Telling people to just change the way they ... study author Barbel Knauper, an associate professor of psychology at ... "But research has shown that if people make a ...
Cached Medicine News:Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 2Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 3Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 4Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Sleepy connected Americans 2Health News:Sleepy connected Americans 3Health News:Sleepy connected Americans 4Health News:Sleepy connected Americans 5Health News:Sleepy connected Americans 6Health News:Leicester leads on heart attack genetic link discovery 2
... Merlin is a superior full-color, auto-focus, desktop ... user in mind, Merlin enables the user ... and white, high contrast positive or high ... magnifier, this optional feature enables the user ...
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
... Economy Incubators available in five different models. ... 1.4 cu. Ft. (39 liters), 2.5 cu. ... (129 liters. Equally important, Precision Economy Incubators ... temperature sensitivity, stability, and uniformity. As a ...
Aspheric diagnostic lens. 90D...
Medicine Products: